Clinical Trials Related to Metastatic Pancreatic Ductal Adenocarcinoma

Related studies linked through entity extraction aliases.

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE2/PHASE3

Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE3

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: PHASE1/PHASE2

Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Status: RECRUITING
Phase: PHASE3

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: PHASE2

OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: EARLY_PHASE1

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Status: RECRUITING
Phase: PHASE2/PHASE3

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

Status: NOT_YET_RECRUITING
Phase: PHASE1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Status: RECRUITING
Phase: PHASE1

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: PHASE1/PHASE2

The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

Status: RECRUITING
Phase: PHASE2

MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Status: RECRUITING
Phase: PHASE1

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Status: WITHDRAWN
Phase: PHASE1

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Status: RECRUITING
Phase: N/A

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Status: WITHDRAWN
Phase: PHASE2

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Status: COMPLETED
Phase: PHASE2